Study of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta Virus
NCT07096193
This study is recruiting at 5 US sites in 4 states, according to its ClinicalTrials.gov record last updated .
Summary
The goals of this clinical study are to first learn more about safety and dosing of the study drug GS-4321 in healthy participants. The study will then learn about the safety and effectiveness of GS-4321 in participants with chronic hepatitis delta (CHD). The primary objective of Phase 1 of this study is to evaluate the safety, tolerability and Pharmacokinetics (PK) of the escalating single doses of GS-4321 administered in healthy participants.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Chronic Hepatitis Delta
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 to 69 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Gilead Sciences
- Last updated on ClinicalTrials.gov
- August 27, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 2
- Investigative Site · Anaheim, CA
- University of California, San Diego - Altman Clinical and Translational Research Institute · La Jolla, CA
Kentucky · 1
- University of Louisville, Clinical Trials Unit · Louisville, KY
Maryland · 1
- University of Maryland, Institute of Human Virology, Clinical Research Unit · Baltimore, MD
New York · 1
- The New York-Presbyterian Hospital · New York, NY
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.